Bulletin of Environment, Pharmacology and Life Sciences Bull. Env. Pharmacol. Life Sci., Vol 10 [11]October 2021 : 146-160 ©2021 Academy for Environment and Life Sciences, India Online ISSN 2277-1808 Journal's URL:http://www.bepls.com CODEN: BEPLAD ORIGINAL ARTICLE



In Silico Studies of PPARy gene related to Diabetes Mellitus and Inflammation

K. S. Ravi Teja¹ and Alpana Joshi^{2*}

¹M.Tech (Bioinformatics) Department of Biomedical and Bioinformatics Engineering, Shobhit Institute of Engineering & Technology, Modipuram, Meerut (UP)

²Department of Agriculture and Agri-informatics, Shobhit Institute of Engineering & Technology,

Modipuram, Meerut (UP)

*E-mail: alpana.joshi@shobhituniversity.ac.in; joshi.alpana@gmail.com

ABSTRACT

Bioinformatics is the improvement of healthcare information of data and knowledge. It uses computational tools and techniques to analyse vast amount of biological data or databases. The diseases such as metabolic disorder, genetic disorder, inborn disorder, rheumatoid arthritis and other inflammatory conditions can be analysed at remediable stage using these bioinformatics and computational methods. These methods or tools which can used to process at genomics and proteomics levels can compare with healthcare data. And also identify the genetic interaction studies and gene variant and also phylogenetic tree analysis. Diabetes is an endrocrinological condition that affects millions of people and can cause myriad health complications. Numerous bioinformatics tools are being used in diabetes research and related inflammation.

Keywords: Diabetes, Inflammation, Genomics, Proteomics, Phylogenetic.

Received 25.06.2021

Revised 13.08.2021

Accepted 11.10.2021

INTRODUCTION

Bioinformatics is the centralised field that can explains the procedure and software tools for demonstrating biological information. Bioinformatics came to read to result and give direction to the vast amount of data through molecular biology techniques. Bioinformatics is the combination of different fields like, software engineering, computer science, and statistics etc. The field of bioinformatics can guise the examination of molecular data quants clinical and diagnostic data for personalised medicine of healthcare. Bioinformatics is used to identify the candidate gene to analyse at genetic basics level, cellular and molecular levels of different populations. The large or vast amount of data from bioinformatics or computational biology and health informatics domains link with analyses and deliver near future of preventive, personalized healthcare cards. [1,2] In basic biology it helps in increase the display of DNA, RNA and 3D protein structures and some additional bio-molecular interactions which can be accelerated advance of gene therapy, genome editing and drug discovery. [3,4]

Type 2 Diabetes Mellitus (Diabetes Mellitus) originates from insulin resistance and impaired β -cell function and create a major health problem throughout the world. Liver is involved in glucose metabolism, including gluconeogenesis, glycogenosis and insulin extraction. Variation of glucose metabolism in liver contributes development of Type 2 diabetes (Diabetes Mellitus). Diabetes often leads to cardiovascular complications which effect shows on patient quality of life. Type 2 Diabetes is mainly caused by genetic factors and environmental influence. To prevent and reduce the complications of Diabetes Mellitus important to analyse the pathophysiological mechanism at genetic level. [5-8] At present with wide use and development of high-throughput sequencing, bioinformatics analysis is a big advantage to understand the Diabetes Mellitus at genetic basis. A research acknowledgement that the methylation of key genes participate in diabetic nephropathy. Studies of mRNA expression profiles at peripheral Diabetes Mellitus from Database so these profiles which will result that which genes will express and which genes will not express in profiles. And also see the regulation of up regulation and down regulation process based on cut off of p-value. And also see study gene interaction levels i.e how other genes are interacting with major causing gene. [9-12]

The peroxisome proliferator activated receptory (*PPARG*) gene is a member of the nuclear hormone receptor superfamily that regulates the transcription of several genes involved in glucose metabolism, adipocyte differentiation, lipid oxidation, angiogenesis and inflammation. Most of the mutation analysis has focused on the coding region of the *PPARG* gene. In different independent studies, the association of the *PPARG* gene with type 2 Diabetes Mellitus has been consistently reported. In the present study, we screened the coding regions of the *PPARG* gene, and examined the association of the *PPARG* gene with type 2 Diabetes Mellitus in the population of West Bengal, India. [13-20]

MATERIAL AND METHODS

The aim of the computational tools is to provide the information about phylogenetic examinations and physiochemical properties of proteins.

A. Gene Identification and Sequence Analyses: The apprehension of biomolecules such as nucleic acid and proteins can be achieved by investigations. Sequence analysis is the subject to analyse DNA, RNA, and Protein sequence to understand structure, function and evolutionary studies.

BLAST (Basic Local Alignment Search Tool): It is homology and similarity search tool. BLAST is the biological database containing amino acids of protein sequences and nucleotides of DNA sequences. BLAST find out patches of sequence similarity rather than best alignment and also produce un-gapped alignments. BLAST is based on explicit statistical theory.

B. Prediction of Protein Structure: Protein structure can be identified or constructed using three dimension structures can be predicted. It is difficult to determine the secondary, tertiary or quaternary structure of proteins so we use X-ray crystallographic studies and bioinformatics tools. Using multiple sequence alignment (MSA) also predict protein structure.

C. Phylogenetic Analysis: It refers to ancestral relationship in a set of species or taxa. The study to work out the ancestral relationship among various species or taxa is called phylogenetic analysis or phylogenetic. It demonstrates to which extent various species or taxa are related to each other and whether one of these species or taxa could be the possible ancestor for rest of species.

Phylogenetic Analysis helps us to understand the similarity among species or individuals, Dissimilarity between species, close relative of species, possible ancestor of a group.

D. Gene Interactions: It occur when two alleles affecting different genes combine within an organism to yield phenotype not simply explained by adding together the phenotype associated with each of two alleles.

E. Comparative Genomics: It is an exciting field of biological research in which researchers use variety or various tools, including computer-based analysis to compare complete genome sequence of different species.

Comparison of gene numbers, gene locations and biological functions of gene, in the genome of different organisms, one object being identify groups of genes that play unique biological role in the organism.

F. Gene variants: It is used to describe the variation in the DNA sequence in each of our genomes.

G. Functional Genomics: Branch of genomics that determine biological functions of genes and their products. Functional genomics (transcriptomics and proteomics) is a global, systematic and comprehensive approach for identification and description of the process and pathways involved in the normal and abnormal state of genes.

It is largely experiment based with a focus on gene functions at the whole genome level using high throughput approaches. High throughput analysis of all expressed genes is also termed as transcriptome analysis.

H. IGSR: The International Genome Sample Resource: It is providing ongoing support for the 1000 Genomes project data. It is ran between 2008 and 2015. It is creating a large public archive of human variation and genotype data. The overview of 1000 Genome project data was the find most genetic variants with frequencies of atleast 1% in the population studied.

The Advantage of this project is development of sequencing technology which can sharply the cost of sequencing. It can provide comprehensive resource of human genetic variation. Data from 1000 genome project was quickly made available to the worldwide scientific community through freely accessible public databases.

I. Gene Mania: find other genes that are related to a set of input genes using a large set of functional association data. Association data include protein and genetic interactions, pathways, co- expression, co-localization and protein domain similarity. You can use Gene Mania to find new members of a pathway or complex find additional genes you may have missed in your screen or find new genes with a specific function such, as protein kinase etc.

J. String: is a database of known and predicted protein-protein interactions. These associations include
direct (physical) and indirect (functional) associations. They stem from computational prediction from
knowledge transfer between organisms, and from interactions and from other primary databases.
Software of Bioinformatics

Soltware of Diolillor line	
Tool and software	Methods and Applications
RAPTORX	Is a software and web server of protein structure and prediction
MEGA	Is designed for comparative analysis of homologous sequences
Network analyst	Web application that enables complex meta-analysis and visualization
String	Is a database of known and predicted protein-protein interactions
Gene Mania	Which can generate hypotheses about gene function and list of genes for
	functional assays

RESULTS AND DISCUSSION

BLAST Analysis of PPARγ gene

Peroxisome Proliferator-activated receptor is the sub family of nuclear receptors. PPARs form heterodimers which regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPARy. The protein encoded by this gene is PPARy and is a regulator of adipocyte differentiation. PPARy has been implicated in the pathology of numerous diseases such as Obesity, diabetes and cancer. Diseases associated with PPARG include Diabetes, Lipodystrophy, Familial partial, and Rheumatoid Arthritis etc. Sequence alignment and BLAST analysis of DNA and protein sequence of PPARy gene transcript variant shows 100% similarity and no gaps in alignment (Figure 1-4).

Homo sapiens peroxisome proliferator activated receptor gamma (PPARG), transcript variant 4, mRNA

Range 1: 1 to	o 1470 🤆	GenBank G	raphics		V Next Match 🔺 Prev
Score 2715 bits(14	70)	Expect 0.0	Identities 1470/1470(100%)	Gaps 0/1470(0%)	Strand Plus/Plus
Query 1	CGGCC	CGACCCGGC	TCCGCCGCGGGCAGGCGGG	GCCCAGCGCACTCGGAGCC	CGAGCCCG 60
Sbjct 1			TCCGCCGCGGGCAGGCGGG	GCCCAGCGCACTCGGAGCC	CGAGCCCG 60
Query 61	AGCCG	CAGCCGCCG	CCTGGGGCGCTTGGGTCGG	CCTCGAGGACACCGGAGAG	GGGCGCCA 120
Sbjct 61	AGCCG	CAGCCGCCG	CCTGGGGCGCTTGGGTCGG	CCTCGAGGACACCGGAGAG	GGGCGCCA 120
Query 121	CGCCG	CCGTGGCCG	CAGAAATGACCATGGTTGA	CACAGAGATGCCATTCTGG	CCCACCAA 180
Sbjct 121	CGCCG	CCGTGGCCG	CAGAAATGACCATGGTTGA	CACAGAGATGCCATTCTGG	CCCACCAA 180
Query 181	CTTTG	GGATCAGCT	CCGTGGATCTCTCCGTAAT	GGAAGACCACTCCCACTCC	TTTGATAT 240
Sbjct 181	CTTTG	GGATCAGCT	CCGTGGATCTCTCCGTAAT	GGAAGACCACTCCCACTCC	TTTGATAT 240
Query 241	CAAGC	ССТТСАСТА	CTGTTGACTTCTCCAGCAT	TTCTACTCCACATTACGAA	GACATTCC 300
Sbjct 241	CAAGC	ССТТСАСТА	CTGTTGACTTCTCCAGCAT	TTCTACTCCACATTACGAA	GACATTCC 300
Query 301	ATTCA	CAAGAACAG	ATCCAGTGGTTGCAGATTA	CAAGTATGACCTGAAACTT	CAAGAGTA 360
Sbjct 301	ATTCA	CAAGAACAG	ATCCAGTGGTTGCAGATTA	CAAGTATGACCTGAAACTT	CAAGAGTA 360
Query 361	ССААА	GTGCAATCA	AAGTGGAGCCTGCATCTCC	ACCTTATTATTCTGAGAAG	ACTCAGCT 420
Sbjct 361		GTGCAATCA	AAGTGGAGCCTGCATCTCC	ACCTTATTATTCTGAGAAG	ACTCAGCT 420
Query 421	CTACA	ATAAGCCTC	ATGAAGAGCCTTCCAACTC	CCTCATGGCAATTGAATGT	CGTGTCTG 480
Sbict 421			ATGAAGAGCCTTCCAACTC		
Figu	re 1: N	ICRI-RU	AST analysis of F	PARY gene of H	omo sapiens is

Sequence ID: NM_005037.6 Length: 1772 Number of Matches: 1

			Alignment	Scores	< 40	40 - 50	50 - 80	80 - 200	>=
D	istri	bution of	f the top 1	11 Blast	Hits	on 100 su	bject seque	ences	
1		1 250	 500	Query I 750	1	1000	1 1250		
	-								
-	_								
	-								
25									
	-								_
		-		-		-	ublic genom hits on 100		
quence perox _{Sequer}	e aligi xisom	nment sho e prolifera	owing comp	olete cove ed recepto	erage o er gamn	f 111 blast na isoform	-	subject seq	
quence perox Sequer See	e align (isom nce ID:) 6 mor	e prolifera NP_056953. Te title(s) ~ o 505 <u>GenPe</u>	owing comp tor-activate 2 Length: 509 ept Graphics	olete cove ed recepto	erage o or gamn of Matche	f 111 blast na isoform s: 1	hits on 100 2 [Homo sapi	subject seq	juence.
perox Sequen See Range Score	e align (isom nce ID: 6 mor 1: 1 t	e prolifera NP_056953. Te title(s) ~ o 505 <u>GenPe</u> Expect 1	owing comp tor-activate .2 Length: 50 ept <u>Graphics</u> Method	olete cove ed recepto 5 Number o	erage o or gamn of Matche	f 111 blast na isoform es: 1	hits on 100 2 [Homo sapi	subject seq ens] d Match 🔺 Prev Gaps	uence. vious Mato
perox Sequen See Range Score	e align (isom nce ID: 6 mor 1: 1 t	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0	tor-activate 2 Length: 50 ept Graphics Method Compositional	ed recepto 5 Number o matrix adju	rage o r gamn of Matche Ider ust. 505	f 111 blast na isoform es: 1 https://www.sities s/505(100%) PFWPTNFGISS	hits on 100 2 [Homo sapi V New Positives 505/505(100%) VDLSVMEDHSHSF	subject seq	uence. vious Mato
perox Sequer See Range Score 1049 I	e align (isom nee ID:) 6 mor 1: 1 t bits(27	e prolifera NP_056953. Te title(s) ~ 0 505 GenPer Expect 1 (13) 0.0 MGETLGDSP MGETLGDSP	tor-activate 2 Length: 509 ept Graphics Method Compositional PIDPESDSFTDT PIDPESDSFTDT	ed recepto 5 Number o matrix adju LSANISQEMT	rage o r gamn of Matche ust. 505 IMVDTEMI	f 111 blast ma isoform s: 1 htties i/505(100%) PFWPTNFGISS PFWPTNFGISS	hits on 100 2 [Homo sapi V New Positives 505/505(100%)	subject seq ens] d Match 🔺 Prev Gaps 5) 0/505(0%) 60	uence. vious Mate
quence perox Sequer See Range Score 1049 I Query	e align (isom (ce ID:) 6 mor 1: 1 t bits(27 1	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 C MGETLGDSP MGETLGDSP MGETLGDSP	tor-activate 2 Length: 50 ept Graphics Method Compositional PIDPESDSFTDT PIDPESDSFTDT PIDPESDSFTDT	ed recepto 5 Number o matrix adju LSANISQEMT LSANISQEMT	Ider Jast. 505 MVDTEMI MVDTEMI MVDTEMI	f 111 blast na isoform es: 1 htities i/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS	hits on 100 2 [Homo sapi 2 [Homo sapi v Net 505/505(100%) VDLSVMEDHSHSF VDLSVMEDHSHSF	subject seq ens] (Match A Prev Gaps () 0/505(0%) 60 60 60	uence. vious Mato
quence perox Sequer See Range Score 1049 I Query Sbjct	e align (isom nce ID:) 6 mor 1: 1 t bits(27 1 1	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect I (13) 0.0 MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP	tor-activate 2 Length: 50 2 Length: 50 2 Compositional 2 DPESDSFTDT 2 DPESDSFTD 2 DP	ed recepto 5 Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV	rage o r gamn f Matche Ider Ist. 505 MVDTEMI MVDTEMI (ADYKYD) (ADYKYD)	f 111 blast ma isoform s: 1 httles (/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK	c hits on 100 2 [Homo sapi V New Positives 505/505(100%) VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF	subject seq ens] d Match Prev Gaps b) 0/505(0%) 60 60 120	uence. vious Mate
quence perox Sequer See Range Score 1049 I Query Sbjct Query	e align (isom (isom (ice ID:)) 6 mor (i 1: 1 t bits(27) 1 1 61	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD	tor-activate tor-activate Length: 50 ept Graphics Method Compositional PIDPESDSFTDT PIDPESDSF	ed recepto 5 Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV	Ider Jst. 505 MVDTEMI MVDTEMI MVDTEMI MVDTEMI MVDTEMI MVDTEMI MDYKYDI MDYKYDI	f 111 blast ma isoform es: 1 htities i/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK	hits on 100 2 [Homo sapi sapi 2 [Homo sapi 2 [Homo sapi 2 [Homo sapi 2 [Homo sapi sapi 2 [Homo sapi 2 [Homo sapi sapi 2 [Homo sapi sapi 2 [Homo sapi sapi 2 [Homo sapi sapi sapi sapi sapi sapi sapi sapi	subject seq ens] (Match A Prev Gaps () 0/505(0%) 60 60 60 120 120	uence. vious Mate
quence perox Sequen See Range Score 1049 I Query Sbjct Query Sbjct Query	e align (isom (isom (ice ID:) () 6 mor () 1: 1 t () () 1 () 1 () 1 () 1 () 1 () 1 () 1 (e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 C MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE	tor-activate tor-activate 2 Length: 50 2 Length: 50 2 Compositional 2 Composit	matrix adju LSANISQEMT LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH	rage o r gamn f Matche Ider Ist. 505 MVDTEMI MVDTEMI MVDTEMI ADYKYDI ADYKYDI ADYKYDI	f 111 blast ma isoform s: 1 htties 5/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI	Inits on 100 2 [Homo sapi 2 [Homo sapi w New 505/505(100%) VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT RLKLIYDRCDLNC RLKLIYDRCDLNC	subject seq ens] d Match A Prev Gaps o) 0/505(0%) 60 60 120 120 180	vious Mate
quence perox Sequer See Range Score 1049 I Query Sbjct Query Sbjct Query Sbjct	e align (isom (isom (ice ID:)) 6 mor (i 1: 1 t (i) (i) (i) (i) (i) (i) (i) (i) (i) (i)	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 C MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE	tor-activate tor-activate 2 Length: 50 ept Graphics Method Compositional PIDPESDSFTDT PIDPESDSFTDT PIDPESDSFTDT PIDPESDSFTDT PISSISTPHYED PSSISTPHYED PSSISTPHYED PSSISTPHYED PSSISLMAIECR PSSISLMAIECR	ed recepto 5 Number o 5 Number o matrix adju LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH VCGDKASGFH	Ider Jack 505 My Drem Ider Jack 505 My DTEMI My DTEMI My DTEMI My DY KYDI JADY KYDI JADY KYDI JADY KYDI JADY KYDI JYGVHACI JYGVHACI	f 111 blast ma isoform es: 1 htities i/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI	c hits on 100 2 [Homo sapi 2 [Homo sapi V Nev Positives 505/505(100% VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT RLKLLYDRCDLNC RLKLLYDRCDLNC	subject seq ens] (Match A Prev Gaps () 0/505(0%) 60 60 120 120 120 180 180	vious Mate
quence perox Sequen See Range Score 1049 I Query Sbjct Query Sbjct Query Sbjct Query	e align (isom nce ID:) 6 mor 1: 1 t bits(27 1 1 61 61 121 121 181	e prolifera NP_056953. Te title(s) ~ o 505 GenPe Expect 1 713) 0.0 C MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE RIHKKSRNK RIHKKSRNK	tor-activate tor-activate ter-a	ed recepto 5 Number o 5 Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH VCGDKASGFH VCGDKASGFH	rage o r gamn f Matche Ider Ist. 505 MVDTEMI M	f 111 blast ma isoform ss: 1 htties 5/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI	Inits on 100 2 [Homo sapi 2 [Homo sapi w New 505/505(100%) VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC DIDQLNPESADLR	subject seq ens] d Match A Prev Gaps 0/505(0%) 60 60 120 120 120 180 180 240	vious Mate
quence perox Sequer See Range Score 1049 I Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query Sbjct	e align (isom (isom (ice ID:)) 6 mor (i 1: 1 t (i) (i) (i) (i) (i) (i) (i) (i) (i) (i)	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 G MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE RIHKKSRNK RIHKKSRNK	tor-activate tor-activate 2 Length: 50 2 Len	ed recepto 5 Number o 5 Number o 5 Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH	Ider Jack 505 Mydrem Ider Jack 505 Mydrem Mydrem Mydrem Mydrycyd Mygyhaci Mygyhaci GrempQal GrempQal	f 111 blast ma isoform es: 1 htities i/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EKEKLLAEISS EKEKLLAEISS	c hits on 100 2 [Homo sapi 2 [Homo sapi V Nev Positives 505/505(100% VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR	subject seq ens] (Match A Prev Gaps () 0/505(0%) 60 60 120 120 120 120 180 180 240 240	vious Mate
quence perox Sequen See Range Score 1049 I Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query	e align (isom nce ID:) 6 mor 1: 1 t bits(27 1 1 61 61 121 121 181 181 241	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 C MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE QLYNKPHEE RIHKKSRNK RIHKKSRNK RIHKKSRNK ALAKHLYDS	tor-activate tor-activate tor-activate ter Graphics Method Compositional PIDPESDSFTDT IDPESDSFTDT IDPESDSFTDT IDPESDSFTDT PFSSISTPHYED FSS	ed recepto 5 Number o 5 Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH	Ider Ider Ider Ist. 505 MVDTEMI MVDTEM	f 111 blast ma isoform ss: 1 httles s/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EKEKLLAEISS EKEKLLAEISS IYDMNSLMMGE	Inits on 100 2 [Homo sapi 2 [Homo sapi w New Positives 505/505(100%) VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT DLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYSEKT VEPASPPYSEKT VEPASPPYSEKT VEPASPPYSEKT VEPASPYSEKT	subject seq ens] d Match A Prev Gaps 0/505(0%) 60 60 120 120 120 180 180 240 240 300	vious Mate
perox Sequer See Range Score 1049 I Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query Sbjct	e align (isom (isom (ice ID:)) 6 mor (i 1: 1 t (i) (i) (i) (i) (i) (i) (i) (i) (i) (i)	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 G MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE QLYNKPHEE RIHKKSRNK RIHKKSRNK RIHKKSRNK RIHKKSRNK	tor-activate tor-activate 2 Length: 50 ept Graphics Method Compositional DPESDSFTDT DPESDSFTDT DPESDSFTDT DFSSISTPHYED PSSISTPHYED PSSISTPHYED PSSISTPHYED PSSISTPHYED PSSISTPHYED PSSISTPHYED CQYCRFQKCLA CQYCRFQKCLA CQYCRFQKCLA CQYCRFQKCLA CQYCRFQKCLA CQYCRFQKCLA CQYCRFQKCLA CQYCRFQKCLA	ed recepto 5 Number o 5 Number o 5 Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH VCGDKASGFH	Ider Jack 505 Mydrem Ider Jack 505 Mydrem Mydrem Mydrem Mydrycyd Mygyhaci Mygyhaci GrempQal GrempQal Chespev Despev Despev	f 111 blast ma isoform ss: 1 htities i/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EKEKLLAEISS EKEKLLAEISS EKEKLLAEISS IYDMNSLMMGE IYDMNSLMMGE	Inits on 100 2 [Homo sapi 2 [Homo sapi v New 505/505(100%) Positives 505/505(100%) VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DKIKFKHITPLQE DKIKFKHITPLQE	subject seq ens] (Match A Prev Gaps () 0/505(0%) 60 60 120 120 120 120 120 120 120 120 120 12	vious Mate
quence perox Sequen See Range Score 1049 I Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query	e align (isom nce ID:) 6 mor 1: 1 t bits(27 1 1 61 61 121 121 181 181 241 241 301	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 C MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE QLYNKPHEE RIHKKSRNK RIHKKSRNK RIHKKSRNK RIHKKSRNK ALAKHLYDS ALAKHLYDS ALAKHLYDS	tor-activate tor-activate ter-a	ed recepto s recepto Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH VCGDKASG	rage o r gamn of Matche if Matche if Matche ist. 505 mvDTEMI M	f 111 blast ma isoform ss: 1 httles 5/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EKEKLLAEISS EKEKLLAEISS EKEKLLAEISS EKEKLLAEISS IYDMNSLMMGE IYDMNSLMMGE IYDMNSLMMGE	Inits on 100 2 [Homo sapi 2 [Homo sapi v New Positives 505/505(100% VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DKIKFKHITPLQE DKIKFKHITPLQE VGVHEIIYTMLAS YGVHEIIYTMLAS	subject seq ens] d Match A Prev Gaps 0/505(0%) 60 60 120 120 120 120 120 120 120 120 120 12	vious Mate
perox Sequer See Range Score 1049 I Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query Sbjct Query Sbjct	e align (isom (isom (ice ID:)) 6 mor (i 1: 1 t (i) (i) (i) (i) (i) (i) (i) (i) (i) (i)	e prolifera NP_056953. Te title(s) ~ o 505 GenPer Expect 1 713) 0.0 C MGETLGDSP MGETLGDSP MGETLGDSP MGETLGDSP DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD DIKPFTTVD QLYNKPHEE QLYNKPHEE QLYNKPHEE RIHKKSRNK RIHKKSRNK RIHKKSRNK RIHKKSRNK ALAKHLYDS ALAKHLYDS ALAKHLYDS	tor-activate tor-activate ter-a	ed recepto s recepto Number o matrix adju LSANISQEMT LSANISQEMT LSANISQEMT LSANISQEMT IPFTRTDPVV IPFTRTDPVV IPFTRTDPVV VCGDKASGFH VCGDKASG	rage o r gamn of Matche if Matche if Matche ist. 505 mvDTEMI M	f 111 blast ma isoform ss: 1 httles 5/505(100%) PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS PFWPTNFGISS LKLQEYQSAIK LKLQEYQSAIK LKLQEYQSAIK EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EGCKGFFRRTI EKEKLLAEISS EKEKLLAEISS EKEKLLAEISS EKEKLLAEISS IYDMNSLMMGE IYDMNSLMMGE IYDMNSLMMGE	Inits on 100 2 [Homo sapi 2 [Homo sapi v New Positives 505/505(100% VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VDLSVMEDHSHSF VEPASPPYYSEKT VEPASPPYYSEKT VEPASPPYYSEKT RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC RLKLIYDRCDLNC DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DIDQLNPESADLR DKIKFKHITPLQE DKIKFKHITPLQE VGVHEIIYTMLAS	subject seq ens] d Match A Prev Gaps 0/505(0%) 60 60 120 120 120 120 120 120 120 120 120 12	vious Mate






Figure 4: BLAST analysis of protein sequence of PPARy gene collected from the public genome databases. Multiple sequence alignment showing complete coverage of 100 blast hits on 100 subject sequence.

Homology Modelling (Swiss modeller) of PPARy (Protein)

Homology modelling is an important technique in structural biology which narrowing the gap between known protein sequences and experimentally determined structures. Peroxisome proliferator-activated receptory (PPAR γ) is a type II nuclear receptor present in adipose tissue, colon and macrophages. It reduces the hyperglycemia associated type II diabetes-related cardiovascular system risk in human beings. Moreover, fatty acid storage and glucose metabolism are regulated by PPAR γ activation in human body. Molecular docking studies have been conducted to characterize the 3-D structure of PPAR γ and ligand binding efficiency. Result suggested 100 % sequence identity of PPAR γ gene (Figure 5).




Figure 5: Homology Modelling (Swiss modeller) of PPARy gene

Phylogenetic studies of PPARy gene using Maximum Likelihood Method

Phylogenetic studies of transcript variant 4, 5 and 7 of PPARγ gene was conducted using Maximum Likelihood Method. Length of branches which represents the genetic distance in a horizontal manner. So the gene IDs like NM 001354667.2 (transcript variant 7) and NM 001330615.2 (transcript variant 5) and NM 005037.6 (transcript variant 4) are closely related species. Length of horizontal lines is called branches. So these branches is divided nodes. Among all 3 species, last 2 species are sister taxa. Nodes represent two species are called clade. Here 0.5 refers the nucleotide present in the alignment (Figure 6 and 7).

NM 001354867.2 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 7 mRNA

NM 001330815.2 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 5 mRNA

______NM 005037.6 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 4 mRNA

Figure 6: Phylogenetic tree of PPARγ gene (DNA sequence) showing relationship between transcript variant 4, 5 and 7.

NP 001381190.1 peroxisome proliferator-activated receptor gamma
NP 001381193.1 peroxisome proliferator-activated receptor gamma
_sp P37231.3 PPARG HUMAN RecName:

Figure 7: Phylogenetic tree of PPARy gene (protein sequence) showing relationship between transcript variant 4, 5 and 7.

Phylogenetic studies of PPARy gene using Neighbouring (NJ) Method

NJ method is the neighbour joining method is the contract cluster analysis. NJ tracks nodes as tree 0.5 are the nucleotides per site in the alignment. Here in this diagram represents (transcript variant 4, 5, and 7 are closely related. The branch length of the taxonomical units are applied to respective units of the tree. As a result the star tree became irregular and showed some relationship between the taxonomical units (Figure 8 and 9).

NM 001354867.2 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 7 mRNA
NM 001330615.2 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 5 mRNA
NM 005037.6 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 4 mRNA

-05-1

Figure 8: Phylogenetic tree of PPARγ gene (DNA sequence) using Neighbouring (NJ) Method showing relationship between transcript variant 4, 5 and 7.

- NP 001381190.1 peroxisome proliferator-activated receptor gamma
NP 001361193.1 peroxisome proliferator-activated receptor gamma
sp P37231.3 PPARG HUMAN RecName:

H-02-1

Figure 9: Phylogenetic tree of PPARγ gene (Protein sequence) using Neighbouring (NJ) Method showing relationship between transcript variant 4, 5 and 7.

0.2 is the nucleotide per site of alignment.

Phylogenetic studies of PPARy gene using Minimum Evolution Method Minimum evolution method is the process in which assumption of tree with sum of the smallest branch length. Phylogenetic study indicate that all species are closely related species. So the gene IDs like NM 001354667.2 (transcript variant 7) and NM 001330615.2 (transcript variant 5) are closely related species in which 0.5 is the nucleotide site per alignment (Figure 10).

NM 001354667.2 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 7 mRNA
NM 001330815.2 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 5 mRNA
NM 005037.6 Homo sapiens peroxisome proliferator activated receptor gamma (PPARG) transcript variant 4 mRNA

H_05-1

Figure 10: Phylogenetic tree of PPARγ gene (DNA sequence) using Minimum Evolution Method showing relationship between transcript variant 4, 5 and 7.


Minimum evolution method is the process in which assumption of tree within sum of the smallest branch length. From above diagram all species are closely are related to each other. We need to estimate the mutation rate but overall length of time since divergence and below once it indicates 0.2 nucleotide per site of alignment (Figure 11).




Figure 11: Phylogenetic tree of PPARγ gene (Protein sequence) using Minimum Evolution Method showing relationship between transcript variant 4, 5 and 7.

Phylogenetic studies of PPARy gene using UPGMA Method

UPGMA is the unweighted pair group method with arithmetic mean it is simplified method to construct the phylogenetic tree. This method is suitable for large data sets considering lineages with relatively constant rates of evolution. Phylogenetic tree shows the close relation between NM 005037.6 (transcript variant 4), NM 001330615.2 (transcript variant 5) and NM 001354667.2 (transcript variant 7). In this diagram all residues are closely related to each other. A distance is the difference in one residue between the orders of residues in the sequences (Figure 12 and 13).





Gene Mania analysis of PPARy gene Prediction analysis

GeneMANIA (http://www.genemania.org) is a flexible, user-friendly web interface for generating hypotheses about gene function, analysing gene lists and prioritizing genes for functional assays. Functional relationships between genes, often protein interactions. A major source of predicted data is mapping is known functional relationships from another organism via orthology. Study showing functional relationship between PPARγ and other related genes of metabolic pathways (Figure 14).






Figure 14: Prediction analysis for PPARy gene showing functional relationship between PPARy and other related genes of metabolic pathways.

2. Physical Interaction and Co-localization

Two gene products are linked if they were found to interact in protein-protein interaction. These data has been collected from primary studies from protein interaction data base. Result indicates the physical interaction and co-localization of PPARy and other related proteins (Figure 15 and 16).



Co-expression and Pathway analysis: Two genes are linked if their expression levels are similar across conditions in a gene expression study. Most of the data retrieved from Gene Expression Omnibus (GEO). We collect data i.e. associated with publications of research papers. Two genes are linked they participated in same reaction within pathway (Figure 17-19).



protein domain.

Gene Interactions

Two genes are functionally associated if the effects of disturb of one gene found to be modified by disturb of other gene or second gene (Figure 20).





Figure 20. Gene interaction analysis of PPARy gene.


Genetic analysis of PPARy gene

The study indicates the association of variants with PPAR γ gene. PPAR γ is a protein coding genes and study indicates which variants at genetic and protein levels at different locations. Each variant can be represented with different colours. So in these variant diagram it show how many and what types of variants involved in specific gene (PPAR γ). The result indicates that most of the part is covered with intron variant (Blue colour) similar to this each and every legend indicates a specific variant in the gene. And at that particular location which gene is there or any receptors is present in that particular location can be seen in different colour. All these type of variants can be occurred in different categories of each and every level like prosite pattern, prosite profiles and pfam domain.

Prosite is a database in which it consists of protein families, domains and has functional sites with of amino acids pattern and profiles. Prosite is used for identifying the function of the protein and also identify or any new discovery of protein which is different in structure and function.so we can analyse the known protein functions. And Pfam is a database which consists of accurate and exact classification of protein families and it's domains. So from known functional proteins we can have high point of efficacy (probability) to annotate the genomes.

Prints is a set or collection of finger prints. In the above diagram it provides annotation of protein families and it can be analysed by the tools. These finger prints which consists of motifs and MSA (Multiple Sequence Alignment). These motif can defined of 3 Dimensional structure for molecular binding sites. So fingerprints in which present in between of variation of sequences of family, super family and subfamily. STRING network analysis of PPAR γ gene is conducted to establish functional relationship between pathway related genes (Figure 21 and 22).





	🕸 STRING		Search Download Help	My Data
		ADIPOQ EP300 CREEBP-	OA1 FABP4	
		α Settings > Σ Analysis > ⊞ Expo	rts > 🛞 Clusters > 🕒 More	● Less
	Nodes:			
	Network nodes represent proteins	Node Color	Node Content	
	splice isoforms or post-translational modifica are collapsed, i.e. each node represents all the proteins produced by a single, protein-coding y locus.	tions colored nodes: query proteins and first shell of interaction	empty nodes:	
	Edapor			
	epresent protein-protein associations	Known Interactions	Predicted Interactions	Others
Edges re associat meaning shared f	epresent protein-protein associations tions are meant to be specific and gful, i.e. proteins jointly contribute to a function; this does not necessarily mean physically binding each other.	Known Interactions	Predicted Interactions gene neighborhood gene fusions gene co-occurrence	Others Comparison
associat meaning shared f	tions are meant to be specific and gful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other.		gene neighborhood	etextmining
Edges re associat meaning shared 1 they are Your Input	tions are meant to be specific and gful, i.e. proteins jointly contribute to a function; this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid		e gene neighborhood gene fusions gene fusions gene fusions gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore lipocyte differentiation and glucose	textmining
Edges re associat meaning shared 1 they are four Input	tions are meant to be specific and aful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisoma beta-oxid homeostasis. ARF6 acts as a key n of gut ho [] (505 aa) Functional Partners:	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc fation pathway of fatty acids. Key regulator of ad	gene neighborhood gene fusions gene co-occurrence gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore lipocyte differentiation and glucose et) enhancer. Acts as a critical regulator	Neighborhood Gene Fusion Gene Fusion Cooccurence Coexpression Experiments Experiments Textmining [Homology] Score
Edges re associat meaning shared 1 they are four Input	tions are meant to be specific and gful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key r of gut ho [] (505 aa) Functional Partners: SC1A Peroxisome proliferator-activated r	from curated databases experimentally determined ecceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc fation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2	gene neighborhood gene fusions gene fusions gene co-occurrence roxisome proliferators such as or binds to DNA specific PPAR h as acyl-CoA oxidase. It therefore lipocyte differentiation and glucose e) enhancer. Acts as a critical regulator onal coactivator for steroid receptors an.	Verghborhood Gene Fusion Gene Fusion Cooccurrence Coexpression Cooccurrence Cooccurence Cooccurrence Cooccurrence Cooccure
Edges re associat meaning shared 1 they are four Inpur Predicted PPARC	tions are meant to be specific and ful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key r of gut ho [] (505 aa) Functional Partners: SC1A Peroxisome proliferator-activated r 1 Nuclear receptor coactivator 1, Nuc	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc lation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2 eceptor gamma coactivator 1-alpha; Transcription	gene neighborhood gene fusions gene fusions gene co-occurrence roxisome proliferators such as or binds to DNA specific PPAR h as acyl-CoA oxidase. It therefore lipocyte differentiation and glucose e) enhancer. Acts as a critical regulator onal coactivator for steroid receptors an ilear receptors and stimulates the transce	textmining co-expression co-express
Edges re associat meaning shared I they are four Input PPARC Predicted PPARC PPARC PPARC	tions are meant to be specific and gful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key n of gut ho [] (505 aa) I Functional Partners: SC1A Peroxisome proliferator-activated r 1 Nuclear receptor coactivator 1, Nuc 2 Nuclear receptor coactivator 2, Tra	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc lation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2 eceptor gamma coactivator 1-alpha; Transcriptio clear receptor coactivator that directly binds nuc	gene neighborhood gene fusions gene fusions gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore lipocyte differentiation and glucose contained and control of the second control coactivator for steroid receptors an ilear receptors and stimulates the transc d nuclear receptors. Coactivator of the se	textmining co-expression gene Fusion Gene fusion Gene fusion Cooccuration Gene fusion Cooccuration Gene fusion Cooccuration Gene fusion Cooccuration
Edges re associat meaning shared t they are four Input PPARC Predicted PPARC PPARC PPARC PARC	tions are meant to be specific and ful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key n of gut ho [] (505 aa) I Functional Partners: SC1A Peroxisome proliferator-activated r 1 Nuclear receptor coactivator 1, Nuc 2 Nuclear receptor coactivator 2, Tra 3P CREB-binding protein; Acetylates h	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc lation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2 eceptor gamma coactivator 1-alpha; Transcriptio clear receptor coactivator that directly binds nuc nscriptional coactivator for steroid receptors and	gene neighborhood gene fusions gene fusions gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore lipocyte differentiation and glucose conal coactivator for steroid receptors an lear receptors and stimulates the transco d nuclear receptors. Coactivator of the s activation. Also acetylates non-histone po	textmining co-expression europeanses co-expression co-expr
Edges re associat meaning shared I they are four Input PPARC PPARC PPARC PPARC PPARC PPARC PARC	tions are meant to be specific and ful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key m of gut ho [] (505 aa) Functional Partners: SC1A Peroxisome proliferator-activated r 1. Nuclear receptor coactivator 1, Nuu 2. Nuclear receptor coactivator 2, Tra SP CREB-binding protein; Acetylates h Retinoic acid receptor RXR-alpha; F	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc lation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2 eceptor gamma coactivator 1-alpha; Transcriptio clear receptor coactivator that directly binds nuc nscriptional coactivator for steroid receptors an istones, giving a specific tag for transcriptional a	gene neighborhood gene fusions gene fusions gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore ipocyte differentiation and glucose conal coactivator for steroid receptors an ilear receptors and stimulates the transco d nuclear receptors. Coactivator of the s activation. Also acetylates non-histone po s bind as heterodimers to their target res	textmining co-expression e
Edges re association meaning shared I they are four Input Predicted PPARC Predicted PPARC Predicted PARC PRODE RXRA	 tions are meant to be specific and gful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key n of gut ho [] (505 aa) Functional Partners: SG1A Peroxisome proliferator-activated r Nuclear receptor coactivator 1; Nuc 2 Nuclear receptor coactivator 2; Tra 3P CREB-binding protein; Acetylates h Retinoic acid receptor RXR-alpha; F Q Adiponectin; Important adipokine in 	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc lation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2 eceptor gamma coactivator 1-alpha; Transcription clear receptor coactivator for steroid receptors and istones, giving a specific tag for transcriptional a Receptor for retinoic acid. Retinoic acid receptor	e gene neighborhood gene fusions gene fusions gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore ipocyte differentiation and glucose phancer. Acts as a critical regulator conal coactivator for steroid receptors an- ilear receptors and stimulates the transco d nuclear receptors. Coactivator of the s activation. Also acetylates non-histone p s bind as heterodimers to their target res- ulin sensitivity, with direct anti-diabetic, a	textmining textmining textmining textmining textprison
Edges re associat meaning shared 1 they are four Input Predicted PPARC Predicted PPARC Predicted PARC PRAC PRAC	 tions are meant to be specific and gful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid, response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key n of gut ho [] (505 aa) Functional Partners: SC1A Peroxisome proliferator-activated r Nuclear receptor coactivator 1, Nuclear receptor coactivator 2, Tra Peroxisomal protein; Acetylates h Retinoic acid receptor RXR-alpha; Fuq Adiponectin; Important adipokine in Fatty acid-binding protein, adipocyte. 	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc ation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2 eceptor gamma coactivator 1-alpha; Transcription clear receptor coactivator for steroid receptors and istones, giving a specific tag for transcriptional a Receptor for retinoic acid. Retinoic acid receptor nvolved in the control of fat metabolism and insu	e gene neighborhood gene fusions gene fusions gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore ipocyte differentiation and glucose penhancer. Acts as a critical regulator conal coactivator for steroid receptors an- ilear receptors and stimulates the transce d nuclear receptors. Coactivator of the s activation. Also acetylates non-histone p is bind as heterodimers to their target res- ulin sensitivity, with direct anti-diabetic, a oth long chain fatty acids and retinoic ac	textmining co-expression protein homology Cooccrutence Cooccrutence coexchance co
Edges re associat meaning shared 1 they are four Input Predicted PPARC Predicted PPARC Predicted PARC Predicted PARC PRC PRC PARC PARC PARC PRC PARC PA	tions are meant to be specific and ful, i.e. proteins jointly contribute to a function, this does not necessarily mean physically binding each other. t: Peroxisome proliferator-activated r hypolipidemic drugs and fatty acid response elements (PPRE) and mo controls the peroxisomal beta-oxid homeostasis. ARF6 acts as a key m of gut ho [] (505 aa) Functional Partners: SC1A Peroxisome proliferator-activated r 1 Nuclear receptor coactivator 1; Nuc 2 Nuclear receptor coactivator 2; Tra 3P CREB-binding protein; Acetylates h Retinoic acid receptor RXR-alpha; F 1Q Adiponectin; Important adipokine ii 4 Fatty acid-binding protein, adipocyd Leptin; Key player in the regulation	eceptor gamma; Nuclear receptor that binds per s. Once activated by a ligand, the nuclear receptor dulates the transcription of its target genes, suc lation pathway of fatty acids. Key regulator of ad egulator of the tissue-specific adipocyte P2 (aP2 eceptor gamma coactivator 1-alpha; Transcription clear receptor coactivator for steroid receptors and istones, giving a specific tag for transcriptional a Receptor for retinoic acid. Retinoic acid receptor nvolved in the control of fat metabolism and insi- te; Lipid transport protein in adipocytes. Binds bo	e gene neighborhood gene fusions gene fusions gene co-occurrence coxisome proliferators such as or binds to DNA specific PPAR th as acyl-CoA oxidase. It therefore ipocyte differentiation and glucose penhancer. Acts as a critical regulator conal coactivator for steroid receptors an- ilear receptors and stimulates the transce d nuclear receptors. Coactivator of the s activation. Also acetylates non-histone p is bind as heterodimers to their target res- ulin sensitivity, with direct anti-diabetic, a oth long chain fatty acids and retinoic ac- e released into the circulation, has centr.	textmining co-expression protein homology cocccruence cocccruence protein homology cocccruence cocccruence cocccruence cocccruence cocccruence cocccruence cocccruence cocccruence cocccruence coccccruence coccccruence cocccccruence coccccccccccccccccccccccccccccccc

Homo sapiens

	В	ological Process (GO)		
GO-term	description			et false discovery r
GO:0019216	regulation of lipid m		8 of 373	4.69e-09
GO:0045444		n	6 of 100	7.71e-09
		f pueloshasa containing company d		1.02e-08
			10 of 1424	
00.003132/	negative regulation	or contailer biosynthetic process	10 01 14/9	(more)
				(more)
	M	olecular Function (GO)		
GO-term	description			et false discovery r
GO:0051427				3.46e-15
				5.58e-12
		pecific DNA-binding transcription facto.		7.70e-12
		nding		7.26e-10 1.63e-09
00.0003102	signaling receptor b	nuing	10011313	(more)
	C	llular Component (GO)		
GO-term	description		count in gene s	et false discovery r
			5 of 333	5.43e-05
				0.00016
	transcription factor	complex		0.00034
				0.00064
GO:0032991	protein-containing c	omplex	9 of 4/92	0.00088 (more)
				(more)
	F	eference publications		
publication	(year) title			et false discovery r
		PAR-gamma coactivators in thermoge	. 6 of 8	1.84e-12
	(2016) Different ant	-adipogenic effects of bio-compounds .	8 of 93	3.21e-12
PMID:26445145	5 (2015) RNA-Seq An	lysis of Abdominal Fat in Genetically F.		2.06e-11
PMID:22118082	2 (2011) Dietary lipid			2.06e-11
		referentially Regulates Gene Expressio	. 6 of 21	3.63e-11
				(more)
		KEGG Pathways		
pathway	description			et false discovery r
hsa04919			5 of 115	1.93e-07
hsa04920				1.55e-06
	PPAR signaling path	way		1.55e-06
				6.60e-06
nsa05016	Huntington's disease		4 of 193	3.35e-05 (more)
				(more)
		Reactome Pathways		
		ation of white adiagoute differentiation		et false discovery n
				2.56e-24 4.67e-12
				4.6/e-12 1.94e-11
	RORA activates den	expression		1.94e-11
HSA-400253	Circadian Clock	expression		1.99e-11
				(more)
		UniProt Keywords		
keyword	description			et false discovery r
KW-0090	Biological rhythms		5 of 126	2.50e-07
KW-0010	Activator			1.49e-05
		ion		6.12e-05
				6.12e-05
KW-0219	plabetes mellitus		3 of 77	7.94e-05 (more)
				(more)
	P	FAM Protein Domains		
domain			count in nene s	et false discovery r
		on nuclear receptor coactivator protein		4.13e-05
		per contrasts protein	2 of 2	4.13e-05
PF08832		ctivator	2 of 3	4.13e-05
PF08815			2 of 3	4.13e-05
PF08214			2 of 2	4.13e-05
				(more)
	description		ount in gene set fa	
	Nuclear receptor coacti CBP/0300, atvoical RIN		4 of 5 2 of 2	3.33e-10 4.22e-05
	CBP/p300, atypical RIN	a domain superfamily vator, Ncoa-type, interlocking domai	2 of 2 2 of 3	4.22e-05 4.22e-05
IPR038547 0		vator, RCDa-type, Interlocking domai	2 of 2	4.22e-05
IPR038547 0 IPR037077 M				4.22e-05
IPR038547 0 IPR037077 M IPR037073 M			2 of 2	4.220.03
IPR038547 0 IPR037077 M IPR037073 M	Nuclear receptor coacti		2 of 2	(more)
IPR038547 0 IPR037077 M IPR037073 M	Nuclear receptor coacti Coactivator CBP, KIX do	main superfamily	2 of 2	
IPR038547 (IPR037077) IPR037073) IPR036529 (Nuclear receptor coacti Coactivator CBP, KIX do SMAR	nain superfamily T Protein Domains		(more)
IPR038547 (IPR037077) IPR037073) IPR036529 (domain (Nuclear receptor coacti Coactivator CBP, KIX do SMAR description	nain superfamily T Protein Domains	ount in gene set fa	(more) Ise discovery rate
IPR038547 (IPR037077 I IPR037073 I IPR036529 (domain d SM01250 I	Nuclear receptor coacti Coactivator CBP, KIX do SMAf description Histone acetylation pro	nain superfamily T Protein Domains ein	ount in gene set fai 2 of 2	(more) Ise discovery rate 2.24e-05
IPR038547 0 IPR037077 1 IPR037073 1 IPR036529 0 domain 0 SM01250 F SM01151 1	Nuclear receptor coacti Coactivator CBP, KIX do SMAi description Histone acetylation proi This domain, which is u	main superfamily T Protein Domains cc ein ually found tandemly repeated, is f	ount in gene set fa 2 of 2 2 of 3	(more) Ise discovery rate 2.24e-05 2.24e-05
IPR038547 0 IPR037077 1 IPR037073 1 IPR036529 0 domain 0 SM01250 1 SM01251 1 SM00551 1	Nuclear receptor coacti Coactivator CBP; KIX do SMAI description Histone acetylation pro This domain, which is u TAZ zinc finger, present	main superfamily T Protein Domains cc ein ually found tandemly repeated, is f	ount in gene set fai 2 of 2	(more) Ise discovery rate 2.24e-05
IPR038547 0 IPR037077 I IPR037073 I IPR035073 I IPR036529 0 domain 0 SM01250 F SM01151 T SM00551 T SM00291 2	Nuclear receptor coacti Coactivator CBP; KIX do SMAI description Histone acetylation pro This domain, which is u TAZ zinc finger, present	main superfamily T Protein Domains ein usully found tandemly repeated, is f in p300 and CBP	ount in gene set fa 2 of 2 2 of 3 2 of 2	(more) Ise discovery rate 2.24e-05 2.24e-05 2.24e-05 0.00019 0.00019
IPR038547 0 IPR037077 IP IPR037073 IP IPR037073 IP IPR036529 0 domain 0 SM01250 IP SM01250 IP SM00551 1 SM00291 2 SM00091 IP	Nuclear receptor coacti Coactivator CBP, KIX do SMAI description rilstone acetylation proi This domain, which is u TAZ zinc finger, present Zinc-binding domain, pr AAS domain	main superfamily T Protein Domains ein usully found tandemly repeated, is f in p300 and CBP	ount in gene set fa 2 of 2 2 of 3 2 of 2 2 of 2 2 of 19	(more) Ise discovery rate 2.24e-05 2.24e-05 2.24e-05 0.00019
IPR038547 0 IPR037077 I IPR037073 I IPR037073 I IPR036529 0 domain 0 SM01250 F SM0151 1 SM00551 1 SM00291 2	Nuclear receptor coacti Coactivator CBP, KIX do SMAI description rilstone acetylation proi This domain, which is u TAZ zinc finger, present Zinc-binding domain, pr AAS domain	main superfamily T Protein Domains ein usully found tandemly repeated, is f in p300 and CBP	ount in gene set fa 2 of 2 2 of 3 2 of 2 2 of 2 2 of 19	(more) Ise discovery rate 2.24e-05 2.24e-05 2.24e-05 0.00019 0.00019
IPR038547 0 IPR037077 IP IPR037073 IP IPR037073 IP IPR036529 0 domain 0 SM01250 IP SM01250 IP SM00551 1 SM00291 2 SM00091 IP	Nuclear receptor coacti Coactivator CBP, KIX do SMAI description Histone acetylation pro' This domain, which is u AZ zinc finger, present Linc-binding domain, pr ?AS domain bund	main superfamily T Protein Domains ein usully found tandemly repeated, is f in p300 and CBP	ount in gene set fa 2 of 2 2 of 3 2 of 2 2 of 2 2 of 19	(more) Ise discovery rate 2.24e-05 2.24e-05 2.24e-05 0.00019 0.00019
	C:0019216 C:004544 G:004544 G:004511 G:0005444 G:00051427 G:00051427 G:00051427 G:00051427 G:00051629 G:0005629 G:0005629 G:0005694 G:0005694 G:0005694 G:0005694 G:0005694 G:0005694 G:0005694 G:0005694 G:0005694 G:0005694 G:0009575 G:00	G0-term description G0:0019216 regulation of lipid m G0:004544 fat cell differentiation G0:005944 regulation of lipid m G0:005944 regulation of lipid m G0:004511 rhythmic process G0:0031322 negative regulation of G0:0031327 negative regulation of G0:0051427 hormone receptor bin G0:0051427 hormone receptor bin G0:0051427 hormone receptor bin G0:0005102 signaling receptor bin G0:0005102 signaling receptor bin G0:0005507 nuclear chromatin G0:0005507 nuclear chromatin G0:000552 RNA polymerase II G0:000555 NA polymerase II G0:0005567 transcription factor G0:0005567 RNA polymerase II PMID:2545145 (2016) Different ant PMID:2545145 (2015) NNA-Seq Anc PMID:2545145 (2015) NNA-Seq Anc PMID:25056962 (2017) Chiglitazar Pr PMID:25056962 (2017) Chiglitazar Pr PMID:25056962 (2017) Chiglitazar Pr <td< td=""><td>G0-term description G0:0019216 regulation of lipid metabolic process G0:0048511 rhythmic process G0:0031327 negative regulation of nucleobase containing compound m G0:0031327 negative regulation of cellular biosynthetic process G0:0031327 negative regulation of cellular biosynthetic process G0:00051427 hormone receptor binding G0:00051427 normone receptor binding G0:00051427 normone receptor binding G0:00051427 normone receptor binding G0:0005142 signaling receptor binding G0:0005102 signaling receptor binding G0:0005102 signaling receptor binding G0:0005102 signaling receptor binding G0:0005057 RNA polymerase II transcription factor complex G0:000557 RNA polymerase II transcription factor complex PMID:2445145 (2016) Pathway of PPAR-gamma coactivators in thermoge. PMID:2540349 (2016) Different anti-adjocgenic effects of bio-compounds</td></td<> <td>GO term count in pene s 00019216 regulation of lipid metabolic process 8 of 573 00019216 regulation of lipid metabolic process 8 of 573 00019216 regulation of nucleobase containing compound m 10 of 1249 00019217 negative regulation of cucleobase containing compound m 10 of 1249 00019217 negative regulation of cucleobase containing compound m 10 of 1479 0001922 nuclear receptor binding 7 of 111 000005102 signaling receptor binding 7 of 111 000005102 signaling receptor binding 8 of 501 000005102 signaling receptor binding 0 of 1513 000005102 signaling receptor binding 0 of 1513 00000502 tignaling receptor binding 0 of 1513 00000502 signaling receptor binding 0 of 1513 00000502 tignaling receptor binding 0 of 1513</td>	G0-term description G0:0019216 regulation of lipid metabolic process G0:0048511 rhythmic process G0:0031327 negative regulation of nucleobase containing compound m G0:0031327 negative regulation of cellular biosynthetic process G0:0031327 negative regulation of cellular biosynthetic process G0:00051427 hormone receptor binding G0:00051427 normone receptor binding G0:00051427 normone receptor binding G0:00051427 normone receptor binding G0:0005142 signaling receptor binding G0:0005102 signaling receptor binding G0:0005102 signaling receptor binding G0:0005102 signaling receptor binding G0:0005057 RNA polymerase II transcription factor complex G0:000557 RNA polymerase II transcription factor complex PMID:2445145 (2016) Pathway of PPAR-gamma coactivators in thermoge. PMID:2540349 (2016) Different anti-adjocgenic effects of bio-compounds	GO term count in pene s 00019216 regulation of lipid metabolic process 8 of 573 00019216 regulation of lipid metabolic process 8 of 573 00019216 regulation of nucleobase containing compound m 10 of 1249 00019217 negative regulation of cucleobase containing compound m 10 of 1249 00019217 negative regulation of cucleobase containing compound m 10 of 1479 0001922 nuclear receptor binding 7 of 111 000005102 signaling receptor binding 7 of 111 000005102 signaling receptor binding 8 of 501 000005102 signaling receptor binding 0 of 1513 000005102 signaling receptor binding 0 of 1513 00000502 tignaling receptor binding 0 of 1513 00000502 signaling receptor binding 0 of 1513 00000502 tignaling receptor binding 0 of 1513

Figure 22: STRING analysis of PPARγ genes. Functional partner predictions were based on available experimental data, databases, text-mining, and homology.

CONCLUSION

Diabetes Mellitus is a chronic metabolic disorder caused by relatively deficiency of insulin. It can destroy the pancreatic cells. Genome-wide association data mining for identifying novel Diabetes Mellitus genes involved in cross talk with insulin signalling system and metabolomics useful for risk factors. Diagnosis of

Diabetes Mellitus is far satisfactory and it has pathways that consists of graphical diagrams and genetic interactions and also the preventive measures for Diabetes Mellitus and also find out the genetic studies i.e. of inheritance from parents and to genome. Using gene sequencing we can identify these type of metabolic disorder and also make the protein drug interactions for this disorder then we may know which drug is suitable for a particular protein. Which will not disturb other proteins. Based on WHO Diabetes is a leading disorder in world. It is place in top 10 diseases list. The present study provide useful information analysis of Diabetes Mellitus and inflammation. In future, more datasets is needed for analysis of bias process.

REFERENCES

- 1. Chen, Z., Yuan, W., Liu, T., Huang, D., & Xiang, L. (2019). Bioinformatics analysis of hepatic gene expression profiles in type 2 Diabetes Mellitus. Experimental and therapeutic medicine, 18(6), 4303–4312. https://doi.org/10.3892/etm.2019.8092
- Han, L., Shen, W. J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017). PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPARγ. Future cardiology, 13(3), 279–296. https://doi.org/10.2217/fca-2017-0019
- 3. Kelley, R. and Rouchka, E.C. (2007). Bioinformatics Techniques Used in Diabetes Research. Bioinformatics R-ULBL-2007-02T
- 4. Rughani, A., Friedman, J. E., & Tryggestad, J. B. (2020). Type 2 Diabetes in Youth: the Role of Early Life Exposures. Current diabetes reports, 20(9), 45. https://doi.org/10.1007/s11892-020-01328-6.
- Sikhayeva, N., Talzhanov, Y., Iskakova, A., Dzharmukhanov, J., Nugmanova, R., Zholdybaeva, E., & Ramanculov, E. (2018). Type 2 diabetes mellitus: distribution of genetic markers in Kazakh population. Clinical interventions in aging, 13, 377–388. https://doi.org/10.2147/CIA.S156044.
- 6. Wang, Q., Zhao, Z., Shang, J., & Xia, W. (2014). Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach. Journal of diabetes research, 2014, 763936. https://doi.org/10.1155/2014/763936.
- Ghaedi, H., Bastami, M., Jahani, M. M., Alipoor, B., Tabasinezhad, M., Ghaderi, O., Nariman-Saleh-Fam, Z., Mirfakhraie, R., Movafagh, A., Omrani, M. D., & Masotti, A. (2016). A Bioinformatics Approach to the Identification of Variants Associated with Type 1 and Type 2 Diabetes Mellitus that Reside in Functionally Validated miRNAs Binding Sites. Biochemical genetics, 54(3), 211–221. https://doi.org/10.1007/s10528-016-9713-5.
- Zhong, M., Wu, Y., Ou, W., Huang, L., & Yang, L. (2019). Identification of key genes involved in type 2 diabetic islet dysfunction: a bioinformatics study. Bioscience reports, 39(5), BSR20182172. https://doi.org/10.1042/BSR20182172.
- 9. Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol. 2019 Jun;15(6):327-345. doi: 10.1038/s41581-019-0135-6. PMID: 30894700; PMCID: PMC6889804.
- 10. Thippakorn, C., Schaduangrat, N., & Nantasenamat, C. (2018). Proteomic and bioinformatic discovery of biomarkers for diabetic nephropathy. EXCLI journal, 17, 312–330. https://doi.org/10.17179/excli2018-1150.
- Pordzik, J., Jakubik, D., Jarosz-Popek, J., Wicik, Z., Eyileten, C., De Rosa, S., Indolfi, C., Siller-Matula, J. M., Czajka, P., & Postula, M. (2019). Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review. Cardiovascular diabetology, 18(1), 113. https://doi.org/10.1186/s12933-019-0918-x.
- 12. Sindhu, T., Rajamanikandan, S., & Srinivasan, P. (2012). Computational Prediction of Phylogenetically Conserved Sequence Motifs for Five Different Candidate Genes in Type II Diabetic Nephropathy. Iranian journal of public health, 41(7), 24–33.
- 13. Kapetanios, D., Karkos, C., Giagtzidis, I., Papazoglou, K., Kiroplastis, K., & Spyridis, C. (2016). Vascular calcification biomarkers and peripheral arterial disease. International angiology: a journal of the International Union of Angiology, 35(5), 455–459.
- 14. Ding, L., Fan, L., Xu, X., Fu, J., & Xue, Y. (2019). Identification of core genes and pathways in type 2 diabetes mellitus by bioinformatics analysis. Molecular medicine reports, 20(3), 2597–2608. https://doi.org/10.3892/mmr.2019.10522.
- Feng, X. Y., Ding, T. T., Liu, Y. Y., Xu, W. R., & Cheng, X. C. (2021). In-silico identification of peroxisome proliferatoractivated receptor (PPAR)α/γ agonists from Ligand Expo Components database. Journal of biomolecular structure & dynamics, 39(5), 1853–1864. https://doi.org/10.1080/07391102.2020.1745279.
- Zang, L., Shimada, Y., Nakayama, H., Chen, W., Okamoto, A., Koide, H., Oku, N., Dewa, T., Shiota, M., & Nishimura, N. (2019). Therapeutic Silencing of Centromere Protein X Ameliorates Hyperglycemia in Zebrafish and Mouse Models of Type 2 Diabetes Mellitus. Frontiers in genetics, 10, 693. https://doi.org/10.3389/fgene.2019.00693.
- 17. Christodoulou, M. I., Avgeris, M., Kokkinopoulou, I., Maratou, E., Mitrou, P., Kontos, C. K., Pappas, E., Boutati, E., Scorilas, A., & Fragoulis, E. G. (2019). Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. Scientific reports, 9(1), 1512. https://doi.org/10.1038/s41598-018-37856-1.
- Yang, Z. M., Chen, L. H., Hong, M., Chen, Y. Y., Yang, X. R., Tang, S. M., Yuan, Q. F., & Chen, W. W. (2017). Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. Molecular medicine reports, 15(4), 2143–2153. https://doi.org/10.3892/mmr.2017.6239.

- 19. Larsen, T. M., Toubro, S., & Astrup, A. (2003). PPARγ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity, 27(2), 147–161. https://doi.org/10.1038/sj.ijo.802223.
- 20. Janani, C., & Ranjitha Kumari, B. D. (2015). PPARγ gene--a review. Diabetes & metabolic syndrome, 9(1), 46–50. https://doi.org/10.1016/j.dsx.2014.09.015.

CITATION OF THIS ARTICLE

K. S. Ravi Teja and Alpana Joshi. *In Silico* Studies of PPARγ gene related to Diabetes Mellitus and Inflammation. Bull. Env. Pharmacol. Life Sci., Vol 10[11] October 2021 : 146-160